The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

The present disclosure relates to methods of treating cancers, including metastasized cancers by administering a potent CDK 2/4/6 inhibitor of the formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

##STR00001##

The present disclosure relates to methods of treating cancers, including metastasized cancers by administering a potent CDK 2/4/6 inhibitor of the formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

##STR00001##

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

The invention provides methods for using F16 isoindole small molecules for treatment of solid tumors, particularly brain cancers, such as glioblastoma multiforme (GBM). F16 isoindole is an inhibitor of angiogenesis and is capable of antagonizing tumor vasculature. The invention also provides pharmaceutical compositions including F16 isoindole small molecules.

The invention provides methods for using F16 isoindole small molecules for treatment of solid tumors, particularly brain cancers, such as glioblastoma multiforme (GBM). F16 isoindole is an inhibitor of angiogenesis and is capable of antagonizing tumor vasculature. The invention also provides pharmaceutical compositions including F16 isoindole small molecules.

The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M.sub.4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.